COMPANY INTELLIGENCEWhat the linked records show
MedtechLedger currently links 7 FDA records to the applicant name Endologix, LLC. It includes 1 original PMA approval. 4 entries are PMA supplements. 2 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Jun 7, 2023 to Oct 16, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code QWM appears in 6 of the 7 linked filings. The collection spans 2 FDA product codes and 2 original PMA application families. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P220021, with 6 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 2 linked filings have a current plain-language explanation checked against the recorded FDA decision.
Applicant mailing address recorded by FDA: 3910 Brickway Blvd., Santa Rosa, CA, 95403. Recorded on P220021/S009, decision dated Oct 16, 2026.
Device categories in this collection
Stent Graft, Bypass, Superficial Femoral Artery; System, Endovascular Graft, Aortic Aneurysm Treatment.
Changes described in PMA records
The FDA record for P220021/S009, titled "DETOUR System" with the decision code OK30 and dated 2026-10-16, lists this action as a 30-Day Notice under the supplement reason "Process Change - Manufacturer/Sterilizer/Packager/Supplier." The reported statement describes approval for changes to visual acceptance criteria for TORUS SGDS Latch and Pulley Subassembly components. The record does not explain what those criteria are, what the prior criteria specified, or how the subassembly is manufactured, so those details remain absent from the supplied fields.
The P220021 identifier alone establishes the parent PMA relationship; it does not show that the full DETOUR System was newly approved. The product code QWM, the superficial femoral artery stent graft category, and the applicant Endologix, LLC, appear in the supplied fields. The stated purpose concerns visual acceptance criteria, not proof of safety or clinical effectiveness, and none of the supplied fields report trial data or clinical outcomes.
FDA approval-order wording
approval for changes to visual acceptance criteria for TORUS SGDS Latch and Pulley Subassembly components
Oct 16, 2026 · 30-Day NoticeFDA’s recorded scope: approval of changes to the supplier performing processing of the nitinol wire used in manufacturing of the Alto device.
Jun 3, 2026 · 135 Review Track For 30-Day NoticeFDA’s recorded scope: changes to the stent graft lot release testing and criteria
Jan 22, 2026 · 135 Review Track For 30-Day NoticeFDA’s recorded scope: implementation of new semi-automated crimping equipment and an in-process verification test during manufacturing of the TORUS SG
Dec 23, 2025 · 30-Day NoticeFDA’s recorded scope: a manufacturing site located at Endologix, LLC at 3910 Brickway Blvd., Santa Rosa, CA 95403 for manufacturing the TORUS Stent Graft System and associated manufacturing changes and for an alternate contract sterilizer for the TORUS Stent Graft System located at Steris Isomedix Services at 43425 Business Park Drive, Temecula, CA 92590
Oct 9, 2025 · Normal 180 Day Track No User FeeSubsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.